<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628806</url>
  </required_header>
  <id_info>
    <org_study_id>HSP70CTC</org_study_id>
    <nct_id>NCT04628806</nct_id>
  </id_info>
  <brief_title>Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells</brief_title>
  <acronym>HSP70CTC</acronym>
  <official_title>Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum rechts der Isar, TU München, (TUM), Munich, Germany.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the ability of heat shock protein HSP70 to isolate and quantify&#xD;
      circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.&#xD;
&#xD;
      CTCs will be isolated from peripheral blood before antineoplastic treatment and again after&#xD;
      three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM.&#xD;
&#xD;
      Additionally, imaging parameters of the primary tumor (if available) and metastases will be&#xD;
      analysed and correlations between molecular alterations and imaging parameters will be&#xD;
      assesed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Radiographic response to initial treatment</measure>
    <time_frame>3 months after study enrollment</time_frame>
    <description>radiographic response to treatment will be scored according to RECIST criteria and associated with the number of CTC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between number of CTC isolated with HSP70 compared to EpCAM</measure>
    <time_frame>3 months (at both CTC assessment timepoints)</time_frame>
    <description>the number of CTCs obtained by the novel HSP70 method will be compared to the current gold standard that uses EpCAM. This will be performed for the whole cohort and separate for each tumor site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between differential expressed radiommic parameters between primary tumor and metastases and genetic alterations of the primary tumor and CTCs</measure>
    <time_frame>3 months (at both CTC assessment timepoints)</time_frame>
    <description>computed tomography parameters of primary tumors and metastases will be analysed and parameters extraced that are differentially expressed between both. The same will be performed for genomic mutations and gene expression of the primary tumor and CTC. Correlation analyses will be performed to analyze if radiographic parameters resemble genetic alterations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Melanoma Stage IV</condition>
  <condition>Sarcoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Pancreatic Cancer Stage IV</condition>
  <condition>Prostate Cancer</condition>
  <condition>Breast Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>HSP70CTC</arm_group_label>
    <description>Isolation of circulating tumor cells by HSP70</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CTC isolation by HSP70</intervention_name>
    <description>patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.</description>
    <arm_group_label>HSP70CTC</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      circulating tumor cells and biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        oncological patients treated at a tertiary center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic malignant melanoma (stage IV)&#xD;
&#xD;
          -  Metastatic or unresectable pancreatic adenocarcinoma (stage III or IV)&#xD;
&#xD;
          -  Metastatic breast cancer&#xD;
&#xD;
          -  Metastatic sarcoma&#xD;
&#xD;
          -  Metastatic squamous cell carcinoma of the cervix uteri, head and neck region, vulva,&#xD;
             anus or penis&#xD;
&#xD;
          -  hormone-refractory prostate cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psychiatric disorders that impede adequate informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Zschaeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Zschaeck, MD</last_name>
    <phone>+4930450650764</phone>
    <email>sebastian.zschaeck@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Zschaeck, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Sebastian Zschaeck</investigator_full_name>
    <investigator_title>Doctor Sebastian Zschaeck, principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>patients can sign an optional agreement that their pseudonymized imaging and genetic data will be shared on cancerimagingarchive.net</ipd_description>
    <ipd_time_frame>data will be uploaded 2 years after study completion</ipd_time_frame>
    <ipd_access_criteria>no specific criteria except proper referencing.</ipd_access_criteria>
    <ipd_url>https://www.cancerimagingarchive.net/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

